Cargando…
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
ErbB3, a member of the ErbB family receptors, has a key role in the development and progression of several cancers, including non-small cell lung cancer (NSCLC), and in the establishment of resistance to therapies, leading to the development of anti-ErbB3 therapies. In this study we demonstrated, in...
Autores principales: | Ciardiello, Chiara, Roca, Maria Serena, Noto, Alessia, Bruzzese, Francesca, Moccia, Tania, Vitagliano, Carlo, Gennaro, Elena Di, Ciliberto, Gennaro, Roscilli, Giuseppe, Aurisicchio, Luigi, Marra, Emanuele, Mancini, Rita, Budillon, Alfredo, Leone, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991401/ https://www.ncbi.nlm.nih.gov/pubmed/26862736 http://dx.doi.org/10.18632/oncotarget.7195 |
Ejemplares similares
-
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012) -
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
por: Fattore, Luigi, et al.
Publicado: (2013) -
ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015) -
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
por: Noto, Alessia, et al.
Publicado: (2013) -
Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
por: Fattore, Luigi, et al.
Publicado: (2014)